Business & Economics
Novo Nordisk’s CagriSema Misses Non-Inferiority in Head-to-Head Phase 3, $475 B Valuation Gain Evaporates
On 23 Feb 2026 Novo Nordisk revealed that CagriSema cut weight by 23% after 84 weeks but still under-performed Eli Lilly’s tirzepatide, triggering a double-digit share plunge and wiping out the market-cap windfall Wegovy once created.